Foghorn Therapeutics Inc (FHTX)

Etorro trading 970x250
Foghorn Therapeutics Inc (FHTX) Logo

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. Address: 500 Technology Square, Cambridge, MA, United States, 02139

Foghorn Therapeutics Inc News and around…

Latest news about Foghorn Therapeutics Inc (FHTX) common stock and company :

58 Biggest Movers From Yesterday
24 May, 2022 FinancialContent

Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its ...

Mid-Afternoon Market Update: Nasdaq Gains 150 Points; Copper Up 1.5%
23 May, 2022 FinancialContent

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 600 points on Monday. The Dow traded up ...

Mid-Day Market Update: Dow Rises Over 600 Points; O2Micro International Shares Surge
23 May, 2022 FinancialContent

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 600 points on Monday. The Dow traded up 2.14% ...

30 Stocks Moving In Monday's Mid-Day Session
23 May, 2022 FinancialContent

Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday. Forge ...

66 Biggest Movers From Friday
23 May, 2022 FinancialContent

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 ...

Mid-Day Market Update: Dow Tumbles 200 Points; TherapeuticsMD Shares Jump
20 May, 2022 FinancialContent

U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 200 points on Friday. The Dow traded down 0.64% ...

38 Stocks Moving In Friday's Mid-Day Session
20 May, 2022 FinancialContent

Gainers Leju Holdings Limited (NYSE: LEJU) surged 27.8% to $4.0413. TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 25.6% to ...

Foghorn Stock Plunges After a Patient’s Death. Analysts Say It’s Still a Buy.
20 May, 2022 Yahoo! Finance

The biotech company announced on Thursday that the Food and Drug Administration placed a hold on its leukemia study.

Mid-Morning Market Update: Markets Open Higher; Deere Tops Q2 Views
20 May, 2022 FinancialContent

U.S. stocks traded higher this morning, with the Dow Jones dropping around 150 points on Friday. Following the market opening Friday, ...

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
20 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Recommends COVID-19 ...

Foghorn's stock drops 23% after FDA puts partial hold on clinical trial
20 May, 2022 Yahoo! Finance

Shares of Foghorn Therapeutics Inc. were down 23.7% in premarket trading on Friday, the day after the company said U.S. regulators had placed a partial clinical hold on a Phase 1 clinical trial assessing an experimental therapy for relapsed and/or refractory acute myelogenous leukemia. The Food and Drug Administration has asked for a review of the safety database, as well as information about risk mitigation and clinical activity across doses. Foghorn's stock has declined 49.3% this year, while

10 Biggest Price Target Changes For Friday
20 May, 2022 FinancialContent

Telsey Advisory Group lowered the price target for Best Buy Co., Inc. (NYSE: BBY) from $130 to $90. Best Buy shares rose 0.4% to ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
20 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're closing in on the end of the week for trading as we go over the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
20 May, 2022 FinancialContent

TheFDA has instituted a clinical holdonFoghorn Therapeutics Inc's(NASDAQ: FHTX) Phase 1 dose-escalation ...

Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS
19 May, 2022 Yahoo! Finance

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced the Food and Drug Administration (FDA) has placed the Phase 1 dose escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) on a partial clinical hold. T

Foghorn Therapeutics Provides First Quarter 2022 Corporate Update
09 May, 2022 Yahoo! Finance

- Foghorn continues to advance three phase 1 studies through selectively targeting the chromatin regulatory system; both FHD-286 and FHD-609 continue to dose escalate and enroll patients with initial clinical data expected for FHD-286 in H2 2022 and FHD-609 in 2023 - New preclinical data for FHD-286 presented at AACR provides mechanistic understanding of anti-tumor activity and supports clinical development in AML - More than 10 programs in pre-clinical pipeline evaluating targeted protein degra

Could The Foghorn Therapeutics Inc. (NASDAQ:FHTX) Ownership Structure Tell Us Something Useful?
09 May, 2022 Yahoo! Finance

Every investor in Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) should be aware of the most powerful shareholder groups...

Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting
13 Apr, 2022 Yahoo! Finance

CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced preclinical data supporting the clinical development and mechanistic understanding of BAF inhibition through the BRG1 (SMARCA4) and BRM (SMARCA2) dual inhibitor, FHD-286, for the treatment of cancer, at the 2022 American As

Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
01 Apr, 2022 Yahoo! Finance

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the company will have an oral and late-breaking poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana. Presentations inc

Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength?
23 Mar, 2022 Yahoo! Finance

Foghorn Therapeutics Inc. (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Wall Street Analysts Think Foghorn Therapeutics Inc. (FHTX) Could Surge 85%: Read This Before Placing a Bet
18 Mar, 2022 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 85% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

95 Biggest Movers From Friday
14 Mar, 2022 FinancialContent

Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf ...

Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day
11 Mar, 2022 Yahoo! Finance

CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will participate at the 2022 Guggenheim Targeted Protein Degradation Day which is being held virtually on March 16th, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and result

50 Stocks Moving In Friday's Mid-Day Session
11 Mar, 2022 FinancialContent

Gainers Marygold Companies (NYSE: MGLD) jumped 189.4% to $6.28 after dropping 21% on Thursday. Altamira Therapeutics Ltd. ...

Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook
10 Mar, 2022 Yahoo! Finance

– Initial clinical data for FHD-286 expected in H1’22 and FHD-609 as early as H1’22 – Advancing broad therapeutic pipeline of oncology programs including protein degraders, enzymatic inhibitors and transcription factor disruptors – Entered strategic collaboration in December 2021 with Loxo Oncology at Lilly for five novel oncology targets using Foghorn’s proprietary Gene Traffic Control® Platform, including $380 million in upfront consideration – Significant cash runway including $154.3 million

Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference
28 Feb, 2022 Yahoo! Finance

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will participate on a panel at Cowen’s 42nd Annual Health Care Conference which is being held virtually March 7th through March 9th, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platf

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
28 Feb, 2022 Yahoo! Finance

Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to ad

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
15 Feb, 2022 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 26%
12 Jan, 2022 Yahoo! Finance

The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Foghorn Therapeutics Inc. (FHTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11 Jan, 2022 Yahoo! Finance

Foghorn Therapeutics Inc. (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Foghorn Therapeutics Inc (FHTX) is a NASDAQ Common Stock listed in , ,

970x250